Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

xFOREST Therapeutics

Explore full profile

Innovative RNA-targeted drug discovery leveraging advanced biochemical and computational analysis platforms

Kyoto, JapanFounded 2020Biotech & Life Sciences
Valuation $25–50M Last recorded · 2025
Headcount <100 Current team size
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for xFOREST Therapeutics and the history behind them.

About xFOREST Therapeutics

xFOREST Therapeutics is a pioneering company in the field of RNA-targeted drug discovery. The company specializes in identifying and developing drugs that target RNA structures, a novel approach that has the potential to address multiple diseases. xFOREST Therapeutics operates in the biotechnology and pharmaceutical markets, serving clients ranging from large pharmaceutical companies to research institutions. The company's business model revolves around collaborations and partnerships, such as those with Otsuka and Takeda, to leverage its unique technological assets known as FOREST. These platforms integrate massively parallel biochemical analysis systems and in silico (computer-based) analysis pipelines to analyze thousands of RNA structures. This comprehensive approach enables the rapid and efficient discovery of highly specific RNA binders, which are crucial for developing RNA-targeting drugs. xFOREST Therapeutics generates revenue through research collaborations, licensing agreements, and milestone payments from its partners. The company aims to create a paradigm shift in drug discovery by setting RNA structures as primary targets, thus opening new avenues for therapeutic interventions.

Source: Dealroom company data

At a glance

Founded
2020
Headquarters
Kyoto, Japan
Sector
Biotech & Life Sciences

Investors

4 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed3 investors entered at this stage

  • ANRI
  • Takeda
  • NEDO

Series A1 investor entered at this stage

  • Miyako Capital
Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇯🇵 Japan100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about xFOREST Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See xFOREST Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.